| Martin Johns, | |
|
2000 Memorial Dr, Farrell, PA 16121-1366 | |
| (724) 528-2513 | |
| Not Available |
| Full Name | Martin Johns |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 19 Years |
| Location | 2000 Memorial Dr, Farrell, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043235260 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | MD439400 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Upmc Horizon | Greenville, PA | Hospital |
| Upmc Jameson | New castle, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Upmc Community Medicine Inc | 2062318975 | 690 |
News Archive
Bacterial toxins can wreak mass havoc within cells by shutting down multiple essential functions at once, a new study has found.
Leading national researchers in the fight against breast cancer will convene Oct. 26-29 for the 2010 Advances in Breast Cancer Research Workshop at the University of Arkansas. More than 70 scientists from diverse research areas in science, medicine, engineering and technology will participate. Ten featured speakers will present cutting-edge research on breast cancer diagnosis, therapeutic techniques, treatment and screening.
White House officials said Thursday that biotech drugs (also known as biologics) should only be protected from generics competition for seven years, Reuters reports.
A provision to loosen restriction on physician-owned hospitals found its way into the December tax extension bill, making the national hospital lobby wary that it may be included in the House-Senate negotiations for a long-term compromise. Meanwhile, as always, efforts to repeal Medicare's SGR are complicated.
PharmAthene, Inc. a biodefense company specializing in the development and commercialization of medical countermeasures against chemical and biological threats, announced today that the Department of Health and Human Services, through the Biomedical Advanced Research and Development Authority has modified its existing research and development contract with PharmAthene providing for up to a total of $78.4 million in additional funding, provided that certain milestones are achieved and that all contract options and extensions are exercised by the government, to support the continued advanced development of SparVax™, a second generation recombinant protective antigen (rPA) anthrax vaccine targeted for future procurement in the U.S. Strategic National Stockpile.
› Verified 9 days ago
| Entity Name | Primary Health Network |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417932609 PECOS PAC ID: 9234046228 Enrollment ID: O20031124000553 |
News Archive
Bacterial toxins can wreak mass havoc within cells by shutting down multiple essential functions at once, a new study has found.
Leading national researchers in the fight against breast cancer will convene Oct. 26-29 for the 2010 Advances in Breast Cancer Research Workshop at the University of Arkansas. More than 70 scientists from diverse research areas in science, medicine, engineering and technology will participate. Ten featured speakers will present cutting-edge research on breast cancer diagnosis, therapeutic techniques, treatment and screening.
White House officials said Thursday that biotech drugs (also known as biologics) should only be protected from generics competition for seven years, Reuters reports.
A provision to loosen restriction on physician-owned hospitals found its way into the December tax extension bill, making the national hospital lobby wary that it may be included in the House-Senate negotiations for a long-term compromise. Meanwhile, as always, efforts to repeal Medicare's SGR are complicated.
PharmAthene, Inc. a biodefense company specializing in the development and commercialization of medical countermeasures against chemical and biological threats, announced today that the Department of Health and Human Services, through the Biomedical Advanced Research and Development Authority has modified its existing research and development contract with PharmAthene providing for up to a total of $78.4 million in additional funding, provided that certain milestones are achieved and that all contract options and extensions are exercised by the government, to support the continued advanced development of SparVax™, a second generation recombinant protective antigen (rPA) anthrax vaccine targeted for future procurement in the U.S. Strategic National Stockpile.
› Verified 9 days ago
| Entity Name | Upmc Community Medicine Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558976092 PECOS PAC ID: 2062318975 Enrollment ID: O20040217000388 |
News Archive
Bacterial toxins can wreak mass havoc within cells by shutting down multiple essential functions at once, a new study has found.
Leading national researchers in the fight against breast cancer will convene Oct. 26-29 for the 2010 Advances in Breast Cancer Research Workshop at the University of Arkansas. More than 70 scientists from diverse research areas in science, medicine, engineering and technology will participate. Ten featured speakers will present cutting-edge research on breast cancer diagnosis, therapeutic techniques, treatment and screening.
White House officials said Thursday that biotech drugs (also known as biologics) should only be protected from generics competition for seven years, Reuters reports.
A provision to loosen restriction on physician-owned hospitals found its way into the December tax extension bill, making the national hospital lobby wary that it may be included in the House-Senate negotiations for a long-term compromise. Meanwhile, as always, efforts to repeal Medicare's SGR are complicated.
PharmAthene, Inc. a biodefense company specializing in the development and commercialization of medical countermeasures against chemical and biological threats, announced today that the Department of Health and Human Services, through the Biomedical Advanced Research and Development Authority has modified its existing research and development contract with PharmAthene providing for up to a total of $78.4 million in additional funding, provided that certain milestones are achieved and that all contract options and extensions are exercised by the government, to support the continued advanced development of SparVax™, a second generation recombinant protective antigen (rPA) anthrax vaccine targeted for future procurement in the U.S. Strategic National Stockpile.
› Verified 9 days ago
| Entity Name | University Of Pittsburgh Physicians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619935004 PECOS PAC ID: 8729990239 Enrollment ID: O20040308000883 |
News Archive
Bacterial toxins can wreak mass havoc within cells by shutting down multiple essential functions at once, a new study has found.
Leading national researchers in the fight against breast cancer will convene Oct. 26-29 for the 2010 Advances in Breast Cancer Research Workshop at the University of Arkansas. More than 70 scientists from diverse research areas in science, medicine, engineering and technology will participate. Ten featured speakers will present cutting-edge research on breast cancer diagnosis, therapeutic techniques, treatment and screening.
White House officials said Thursday that biotech drugs (also known as biologics) should only be protected from generics competition for seven years, Reuters reports.
A provision to loosen restriction on physician-owned hospitals found its way into the December tax extension bill, making the national hospital lobby wary that it may be included in the House-Senate negotiations for a long-term compromise. Meanwhile, as always, efforts to repeal Medicare's SGR are complicated.
PharmAthene, Inc. a biodefense company specializing in the development and commercialization of medical countermeasures against chemical and biological threats, announced today that the Department of Health and Human Services, through the Biomedical Advanced Research and Development Authority has modified its existing research and development contract with PharmAthene providing for up to a total of $78.4 million in additional funding, provided that certain milestones are achieved and that all contract options and extensions are exercised by the government, to support the continued advanced development of SparVax™, a second generation recombinant protective antigen (rPA) anthrax vaccine targeted for future procurement in the U.S. Strategic National Stockpile.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Martin Johns, 200 Lothrop St, Suite 9055 Forbes Tower, Pittsburgh, PA 15213-2536 Ph: () - | Martin Johns, 2000 Memorial Dr, Farrell, PA 16121-1366 Ph: (724) 528-2513 |
News Archive
Bacterial toxins can wreak mass havoc within cells by shutting down multiple essential functions at once, a new study has found.
Leading national researchers in the fight against breast cancer will convene Oct. 26-29 for the 2010 Advances in Breast Cancer Research Workshop at the University of Arkansas. More than 70 scientists from diverse research areas in science, medicine, engineering and technology will participate. Ten featured speakers will present cutting-edge research on breast cancer diagnosis, therapeutic techniques, treatment and screening.
White House officials said Thursday that biotech drugs (also known as biologics) should only be protected from generics competition for seven years, Reuters reports.
A provision to loosen restriction on physician-owned hospitals found its way into the December tax extension bill, making the national hospital lobby wary that it may be included in the House-Senate negotiations for a long-term compromise. Meanwhile, as always, efforts to repeal Medicare's SGR are complicated.
PharmAthene, Inc. a biodefense company specializing in the development and commercialization of medical countermeasures against chemical and biological threats, announced today that the Department of Health and Human Services, through the Biomedical Advanced Research and Development Authority has modified its existing research and development contract with PharmAthene providing for up to a total of $78.4 million in additional funding, provided that certain milestones are achieved and that all contract options and extensions are exercised by the government, to support the continued advanced development of SparVax™, a second generation recombinant protective antigen (rPA) anthrax vaccine targeted for future procurement in the U.S. Strategic National Stockpile.
› Verified 9 days ago
Park Bateson, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2000 Green St, Building A Suite 2, Farrell, PA 16121 Phone: 724-981-3070 | |
Dr. Lindsay Louise Graham, D.O. Family Medicine Medicare: Medicare Enrolled Practice Location: Shenango Valley Family Medicine, 2000 Memorial Drive, Suite B, Farrell, PA 16121 Phone: 724-528-2513 | |
Dustin Ross Stanley, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2200 Memorial Dr, Farrell, PA 16121 Phone: 724-981-3500 | |
Meredith Deist, Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 2200 Memorial Dr, Farrell, PA 16121 Phone: 724-983-7507 Fax: 724-983-7930 | |
Catherine M Novosel, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2200 Memorial Dr, Farrell, PA 16121 Phone: 724-981-3500 | |
Brishti Biswas, Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 2200 Memorial Dr, Graduatemedical Education, Farrell, PA 16121 Phone: 724-981-3500 |